PYRIDOSTIGMINE BROMIDE solution

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE - UNII:19QM69HH21)

から入手可能:

Acella Pharmaceuticals, LLC

投与経路:

ORAL

処方タイプ:

PRESCRIPTION DRUG

適応症:

Pyridostigmine bromide is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.

製品概要:

Pyridostigmine Bromide Oral Solution, USP, 60 mg pyridostigmine bromide per teaspoonful (5 mL) and 5% alcohol — bottles of 16 fluid ounces (1 pint) (NDC 42192-626-16) Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).

認証ステータス:

Abbreviated New Drug Application

製品の特徴

PYRIDOSTIGMINE BROMIDE- PYRIDOSTIGMINE BROMIDE SOLUTION
ACELLA PHARMACEUTICALS, LLC
----------
PYRIDOSTIGMINE BROMIDE ORAL SOLUTION USP
DESCRIPTION
Pyridostigmine bromide is an orally active cholinesterase inhibitor.
Chemically,
pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide
dimethylcarbamate.
Its structural formula is:
Pyridostigmine bromide is available as an oral solution containing 60
mg pyridostigmine
bromide per teaspoonful in a vehicle containing 5% alcohol, glycerin,
lactic acid, sodium
benzoate, sorbitol, sucrose, FD&C Red No. 40, FD&C Blue No. 1, flavors
and water.
ACTIONS
Pyridostigmine bromide inhibits the destruction of acetylcholine by
cholinesterase and
thereby permits freer transmission of nerve impulses across the
neuromuscular
junction. Pyridostigmine is an analog of neostigmine (Prostigmin
), but differs from it in
certain clinically significant respects; for example, pyridostigmine
is characterized by a
longer duration of action and fewer gastrointestinal side effects.
INDICATION
Pyridostigmine bromide is useful in the treatment of myasthenia
gravis.
CONTRAINDICATIONS
Pyridostigmine bromide is contraindicated in mechanical intestinal or
urinary obstruction,
and particular caution should be used in its administration to
patients with bronchial
®
asthma. Care should be observed in the use of atropine for
counteracting side effects,
as discussed below.
WARNINGS
Although failure of patients to show clinical improvement may reflect
underdosage, it
can also be indicative of overdosage. As is true of all cholinergic
drugs, overdosage of
pyridostigmine may result in cholinergic crisis, a state characterized
by increasing
muscle weakness which, through involvement of the muscles of
respiration, may lead to
death. Myasthenic crisis due to an increase in the severity of the
disease is also
accompanied by extreme muscle weakness, and thus may be difficult to
distinguish
from cholinergic crisis on a symptomatic basis. Such differentiation
is extremely
important, since increases in doses of